Skip to main content
SpringerLink
Log in

Evaluation of Mutations in 23S rRNA, rdxA and frxA Genes of Helicobacter pylori in Paraffin-Embedded Gastric Biopsy Specimens from Iranian Gastric Cancer and Gastritis Patients

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

Helicobacter pylori (H. pylori) infection is considered as one of the main cause of gastric cancer. Treatment failure of the infection often occurs due to antibiotic resistance. Herein, we aimed to evaluate the mutations in 23S rRNA gene of H. pylori which are associated with clarithromycin resistance and in rdxA and frxA genes of the bacterium which may be associated with metronidazole resistance, in paraffin-embedded gastric biopsies from patients with gastric adenocarcinoma and gastritis in Tabriz, the northwest of Iran.

Methods

In the study, 80 paraffin-embedded tissue sections from 40 gastric cancer and 40 gastritis patients in the Imam Reza hospital, Tabriz, Iran were collected. The existence of ureC gene was verified by PCR method. Genotypical clarithromycin resistance was investigated by real-time PCR method and determination of the melting temperature. PCR reaction and sequencing were used for the evaluation of mutations in rdxA and frxA genes.

Results

The results of ureC amplification showed that DNA of H. pylori was present in the 82.66% of the obtained DNA samples. About 45.16% of samples were resistant to the clarithromycin and 53.22% of them were resistant to the metronidazole. Based on the results from real-time PCR, the frequency of mutations was as follow A2143G 64.28%, A2142G 44.44% and A2142C 1.11%. The mutations of rdxA gene were 66.66% missense, 30.30% frameshift and 3.03% non-sense. The mutations of frxA gene were 36.36% missense, 54.54% frameshift and non-sense 9.09%.

Conclusion

A2143G mutation is the most frequent mutation among clarithromycin resistant genes in Iran. Also, missense and frameshift mutations are frequent in rdxA and frxA genes. Screening for these mutations could help researchers to investigate the most effective anti-H. pylori antibiotics and to prevent antibiotic resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sitarz R, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239.

    Article  CAS  Google Scholar 

  2. Rugge M, Fassan M, Graham DY. Epidemiology of gastric cancer, Gastric Cancer. New York: Springer; 2015. pp. 23-34.

  3. Karimi P, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomark Prev. 2014;23(5):700–13.

    Article  Google Scholar 

  4. Díaz P, et al. Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression. Front Microbiol. 2018;9:5.

    Article  Google Scholar 

  5. Cancer, I.A.f.R.o. Schistosomes, liver flukes and Helicobacter pylori, vol. 61: IARC Lyon; 1994;61:1–241

  6. Herrera V, Parsonnet J. Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect. 2009;15(11):971–6.

    Article  CAS  Google Scholar 

  7. Kao C-Y, Sheu B-S, Wu J-J. Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis. Biom J. 2016;39(1):14–23.

    Google Scholar 

  8. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. The global emergence of helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–33.

    Article  CAS  Google Scholar 

  9. Zagari RM, et al. Treatment of helicobacter pylori infection: a clinical practice update. Eur J Clin Investig. 2018;48(1):e12857.

    Article  Google Scholar 

  10. Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin. 2011;95(4):761–91.

    CAS  Google Scholar 

  11. Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, et al. First-line helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut. 2018;67(1):20–7.

    Article  CAS  Google Scholar 

  12. Chen J, et al. Application of next-generation sequencing to characterize novel mutations in clarithromycin-susceptible helicobacter pylori strains with A2143G of 23S rRNA gene. Ann Clin Microbiol Antimicrob. 2018;17(1):10.

    Article  Google Scholar 

  13. De Francesco V, et al. Change of point mutations in helicobacter pylori rRNA associated with clarithromycin resistance in Italy. J Med Microbiol. 2014;63(3):453–7.

    Article  Google Scholar 

  14. Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure–cytotoxicity and resistance mechanisms. J Antimicrob Chemother. 2017;73(2):265–79.

    Article  Google Scholar 

  15. Doron SI, et al. Mechanisms of Resistance in Metronidazole. In: Antimicrobial Drug Resistance: Switzerland: Springer; 2017. p. 281–7.

  16. Vala MH, et al. Evaluation of clarithromycin resistance among Iranian Helicobacter pylori isolates by E-Test and real-time polymerase chain reaction methods. Jundishapur J Microbiol. 2016;9(5):e 29839.

  17. Savoldi A, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372–1382. e17.

    Article  Google Scholar 

  18. Abadi AT, et al. High frequency of A2143G mutation in clarithromycin-resistant helicobacter pylori isolates recovered from dyspeptic patients in Iran. SaudiJ Gastroenterol. 2011;17(6):396.

    Article  Google Scholar 

  19. Eghbali Z, et al. Detection of 23SrRNA mutations strongly related to clarithromycin resistance in Helicobacter pylori strains isolated from patients in the north of Iran. Jundishapur J Microbiol. 2016;9(2):e29694.

  20. Tajbakhsh S, et al. Prevalence of A2143G and A2144G point mutations responsible for clarithromycin resistance among helicobacter pylori strains in Bushehr, Iran Avicenna. J Clin Microb Infec. 2016;3:e36521.

    Google Scholar 

  21. Falsafi T, Mobasheri F, Nariman F, Najafi M. Susceptibilities to different antibiotics of helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran. J Clin Microbiol. 2004;42(1):387–9.

    Article  CAS  Google Scholar 

  22. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline--comparison of three 3-year studies. Arch Iran Med. 2010;13(3):177–87.

    CAS  PubMed  Google Scholar 

  23. Farzi, N., et al., High prevalence of antibiotic resistance in Helicobacter pylori isolates from Iran: importance of functional and mutational analysis of resistance genes and virulence genotyping. BioRxiv, 2019: p. 569814.https://doi.org/10.1101/569814.

  24. Mahmoudi S, et al. Antibiotic susceptibility of helicobacter pylori strains isolated from Iranian children: high frequency of A2143G point mutation associated with clarithromycin resistance. J Global Antimicrob Resist. 2017;10:131–5.

    Article  Google Scholar 

  25. Mirzaei N, et al. The mutation of the rdxA gene in metronidazole-resistant helicobacter pylori clinical isolates. Adv Biomed Res. 2014;3. https://doi.org/10.4103/2277-9175.128469.

  26. Alfizah H, et al. Resistotype of helicobacter pylori isolates: the impact on eradication outcome. J Med Microbiol. 2014;63(5):703–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by Molecular Medicine Research Center, Bio-medicine Institute, Tabriz University of Medical Sciences, and Tabriz, Iran.

Funding

This work was funded by the Molecular Medicine Research Center, Bio-medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran (grant number: 64015) IR.TBZMED.REC.1398.923.

Author information

Authors and Affiliations

  1. Department of Cardiothoracic Surgery, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

    Samad Beheshtirouy

  2. Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Shirin Eyvazi

  3. Molecular Medicine Research Center, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran

    Shirin Eyvazi & Vahideh Tarhriz

  4. Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

    Vahideh Tarhriz

Authors
  1. Samad Beheshtirouy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shirin Eyvazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vahideh Tarhriz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Shirin Eyvazi or Vahideh Tarhriz.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beheshtirouy, S., Eyvazi, S. & Tarhriz, V. Evaluation of Mutations in 23S rRNA, rdxA and frxA Genes of Helicobacter pylori in Paraffin-Embedded Gastric Biopsy Specimens from Iranian Gastric Cancer and Gastritis Patients. J Gastrointest Canc 52, 207–211 (2021). https://doi.org/10.1007/s12029-020-00386-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00386-z

Keywords

Search

Navigation